Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CADM2 antisense RNA 1 (CADM2-AS1)
- Target
- CADM2-AS1
- Molecular classification
- Long noncoding RNA, Antisense RNA
01
Overview
CADM2 antisense RNA 1 (CADM2-AS1) is a long noncoding RNA identified in human tissues as being aberrantly expressed in several cancers, most notably in metastatic gastric cancer. It promotes metastasis in gastric cancer by sponging and downregulating miR-5047, resulting in increased NOTCH4 mRNA expression and enhanced epithelial-mesenchymal transition (EMT). Knockdown of CADM2-AS1 inhibits cancer cell migration and EMT progression. CADM2-AS1 is not a protein-coding gene and thus is not a direct therapeutic target for drugs but may be a relevant biomarker or an indirect target for RNA-based or genetic therapies.
- Other names
- CADM2-AS1CADM2 antisense RNA 1
02
Mechanism of action
Acts as a molecular sponge for miR-5047 (and possibly other miRNAs), which leads to upregulation of NOTCH4 mRNA and promotes metastasis
03
Biological functions
Regulation of gene expressionRegulation of epithelial-mesenchymal transition (EMT)Promotion of cancer metastasis (not via signaling or direct cell cycle regulation, but through miRNA regulation and post-transcriptional effects)
04
Disease associations
Cancer (especially gastric cancer metastasis)
05
Biomarkers
Potential biomarker for metastatic gastric cancer
Beyond the preview
Go deeper on CADM2 antisense RNA 1 (CADM2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CADM2 antisense RNA 1 (CADM2-AS1).